Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

290 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management and two-year long-term clinical outcome of acute coronary syndrome in Japan: prevention of atherothrombotic incidents following ischemic coronary attack (PACIFIC) registry.
Daida H, Miyauchi K, Ogawa H, Yokoi H, Matsumoto M, Kitakaze M, Kimura T, Matsubara T, Ikari Y, Kimura K, Tsukahara K, Origasa H, Morino Y, Tsutsui H, Kobayashi M, Isshiki T; PACIFIC investigators. Daida H, et al. Among authors: isshiki t. Circ J. 2013;77(4):934-43. doi: 10.1253/circj.cj-13-0174. Epub 2013 Mar 15. Circ J. 2013. PMID: 23502993 Free article. Clinical Trial.
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention.
Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Ikeda Y, Nakamura M, Saito S; PRASFIT-Elective Investigators. Isshiki T, et al. Circ J. 2014;78(12):2926-34. doi: 10.1253/circj.cj-14-0266. Epub 2014 Oct 21. Circ J. 2014. PMID: 25342212 Free article. Clinical Trial.
Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: post-hoc analysis of the randomized PRASFIT-ACS study.
Nakamura M, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Ikeda Y, Saito S. Nakamura M, et al. Among authors: isshiki t. Int J Cardiol. 2015 Mar 1;182:541-8. doi: 10.1016/j.ijcard.2015.01.026. Epub 2015 Jan 8. Int J Cardiol. 2015. PMID: 25679803 Free article.
Impact of Arterial Access Route on Bleeding Complications in Japanese Patients Undergoing Percutaneous Coronary Intervention- Insight From the PRASFIT Trial.
Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nishikawa M, Miyazaki S, Tanaka Y, Nakamura M; PRASFIT-ACS and PRASFIT-Elective Investigators. Saito S, et al. Among authors: isshiki t. Circ J. 2015;79(9):1928-37. doi: 10.1253/circj.CJ-15-0276. Epub 2015 Jun 4. Circ J. 2015. PMID: 26040334 Free article. Clinical Trial.
No association between on-treatment platelet reactivity and bleeding events following percutaneous coronary intervention and antiplatelet therapy: A post hoc analysis.
Nishikawa M, Isshiki T, Kimura T, Ogawa H, Yokoi H, Miyazaki S, Ikeda Y, Nakamura M, Takita A, Saito S; PRASFIT-ACS (PRASugrel compared with clopidogrel For Japanese patIenTs with Acute Coronary Syndrome undergoing percutaneous coronary intervention) Investigators. Nishikawa M, et al. Among authors: isshiki t. Thromb Res. 2015 Nov;136(5):947-54. doi: 10.1016/j.thromres.2015.09.014. Epub 2015 Sep 21. Thromb Res. 2015. PMID: 26460279 Free article. Clinical Trial.
Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
Ogawa H, Isshiki T, Kimura T, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Ikeda Y, Nakamura M, Tanaka Y, Saito S. Ogawa H, et al. Among authors: isshiki t. J Cardiol. 2016 Jul;68(1):29-36. doi: 10.1016/j.jjcc.2015.07.019. Epub 2015 Oct 29. J Cardiol. 2016. PMID: 26521100 Free article. Clinical Trial.
290 results